All In Biotech

Drug Trial Radar · NCT04008797

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

301

Planned (sponsor's estimate)

Start

Jul 11, 2019

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Conditions

  • Endometrial Neoplasms
  • Neoplasms
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Colorectal Neoplasms

Interventions

  • E7386Drug

    E7386 dosing.

  • LenvatinibDrug

    Lenvatinib dosing.

  • DoxorubicinDrug

    Doxorubicin dosing.

  • PaclitaxelDrug

    Paclitaxel dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)Time frame: Cycle 0 (Cycle 0 length=6 or 7 days) up to Cycle 1 (Cycle 1 length=28 days)
  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (up to approximately 90 months)
  3. Dose Optimization Part: Objective Response Rate (ORR) per RECIST 1.1 by Investigator AssessmentTime frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 90 months)

Locations

106 sites in 10 countries. Site status is shown where the registry gives one.

  • UAMS

    Little Rock, Arkansas

  • University of California San Diego (UCSD) - Moores Cancer Center(All)

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Pasadena Liver Center

    Pasadena, California

  • California Pacific Medical Center

    San Francisco, California

  • UCLA University of California - Los Angeles

    Santa Monica, California

  • John Muir Clinical Research

    Walnut Creek, California

  • University of Colorado Cancer Center - Anschutz Medical Campus

    Aurora, Colorado

  • Uni. Of Miami- Sylvester Cancer Centre

    Miami, Florida

  • Florida Cancer Specialists - South

    Sarasota, Florida

  • Florida Cancer Specialists - East

    West Palm Beach, Florida

  • Women's Cancer Care - Covington, LA

    Covington, Louisiana

  • University Of Mississippi Medical Center

    Jackson, Mississippi

  • Kansas City Research Institute

    Kansas City, Missouri

  • Perlmutter Cancer Center- NYU Langone Health

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center (MMC) - Jack D. Weiler Hospital

    The Bronx, New York

  • MetroHealth Medical Center

    Cleveland, Ohio

  • ProMedica Flower Hospital

    Sylvania, Ohio

  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma

  • Medical University of South Carolina

    Charleston, South Carolina

  • Sanford Cancer Centre

    Sioux Falls, South Dakota

  • Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • University of Texas Southwestern Medical

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson/University of Washington Cancer Consortium

    Seattle, Washington

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada

  • CHUM, Unit for Innovative Therapies

    Montreal, Quebec, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Beijing Cancer Hospital

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • The First Bethune Hospital of Jilin University

    Changchun, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, China

  • Sun Yan-sen University Cancer Center

    Guangzhou, China

  • Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University

    Guangzhou, China

  • Cancer Hospital of Shandong First Medical University

    Jinan, China

  • Yunnan Cancer Hospital

    Kunming, China

  • Fudan University Cancer Center

    Shanghai, China

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.